Skip to main content

Muscular Dystrophy and cannabis in Pennsylvania

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
30-day supply as certif…
POSSESSION
$50/yr
STATE FEE
7–21 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Pennsylvania statute and program

The Pennsylvania Medical Marijuana Program is the operating authority for Pennsylvania patient certification. The authoritative legal text is: 35 P.S. §§ 10231.101 – 10231.2110: Medical Marijuana Act. The program portal is at Pennsylvania Medical Marijuana Program.

What the evidence says about cannabis and Muscular Dystrophy

Muscular dystrophy refers to a group of more than 30 inherited genetic disorders characterized by progressive muscle weakness and degeneration caused by mutations in genes encoding proteins that maintain muscle-fiber integrity. The major clinical subtypes include:

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Muscular Dystrophy page.

How to qualify in Pennsylvania

The Pennsylvania Medical Marijuana Program requires the following registration steps for a Muscular Dystrophy patient (or any qualifying diagnosis):

  1. Register through the Pennsylvania Medical Marijuana Program patient portal. Pennsylvania requires the patient to register first, before seeing a practitioner. Patients create an account at the Department of Health Medical Marijuana Program online registry using their Pennsylvania driver license or state ID. The portal assigns a patient ID number that the patient then takes to a certifying practitioner.
  2. Get certified by a PA-registered practitioner. A Pennsylvania-licensed physician registered with the Medical Marijuana Program must evaluate the patient for one of the enumerated serious medical conditions under 35 P.S. §10231.103 (cancer, HIV/AIDS, ALS, Parkinson’s, MS, epilepsy, glaucoma, intractable seizures, IBD, neuropathies, Huntington’s, Crohn’s, PTSD, severe chronic pain, terminal illness, sickle cell, autism, anxiety disorders, Tourette’s, dyskinetic and spastic movement disorders). The practitioner issues an electronic certification.
  3. Pay the $50 state ID card fee. After certification appears in the patient’s portal account, the patient pays the $50 annual identification card fee online. The fee is reduced or waived for patients on Medicaid, PACE/PACENET, CHIP, SNAP, or WIC under PA Department of Health rules.
  4. Receive your card and purchase from a PA dispensary. Pennsylvania medical marijuana ID cards arrive by mail within roughly 7 to 14 business days. Patients may purchase up to a 90-day supply per visit (no flower restrictions since 2018) from any Pennsylvania licensed dispensary. Cards renew annually with a new practitioner certification.
State registration fee
$50
Physician visit (typical)
$150–$250
Certification to card
7–21 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Pennsylvania registration steps, fees, and reciprocity rules, see the Pennsylvania cannabis-laws page.

ICD-10 code

A certifying physician documenting Muscular Dystrophy for the Pennsylvania medical cannabis program will typically record ICD-10 G71.0 or SNOMED-CT 76670001 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Pennsylvania list Muscular Dystrophy as a qualifying condition for medical cannabis?

No. Pennsylvania's qualifying-condition list does not currently include Muscular Dystrophy, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Muscular Dystrophy in Pennsylvania have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Pennsylvania program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a Pennsylvania medical marijuana card for Muscular Dystrophy?

Because Pennsylvania does not currently list Muscular Dystrophy as a qualifying condition, a card for Muscular Dystrophy alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Pennsylvania who is registered with Pennsylvania Medical Marijuana Program and willing to evaluate Muscular Dystrophy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Pennsylvania does not honor out-of-state cards, so the certification process has to originate inside the state. The state minimum patient age is 18; minors generally require a parent or legal guardian to act as caregiver. The authoritative source for the current process is the Pennsylvania Medical Marijuana Program site at https://www.pa.gov/agencies/health/programs/medical-marijuana; the state updates fees, forms, and physician registration rules periodically.

What does the evidence say about cannabis for Muscular Dystrophy?

For Muscular Dystrophy, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Muscular Dystrophy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Muscular Dystrophy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Muscular Dystrophy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Muscular Dystrophy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. 35 P.S. §§ 10231.101 – 10231.2110: Medical Marijuana Actaccessed May 15, 2026
  2. PA Department of Health: Medical Marijuanaaccessed May 15, 2026
  3. NORML: Pennsylvania Lawsaccessed May 15, 2026
  4. 35 P.S. §780-113(a)(31): Possession penalties (PA Controlled Substance Act)accessed May 17, 2026
  5. 75 Pa.C.S. §1532(c): Driver license suspension on drug convictionaccessed May 17, 2026
  6. 75 Pa.C.S. §3802: Driving under the influence (DUI)accessed May 17, 2026
  7. Pennsylvania General Assembly bill search and trackeraccessed May 17, 2026
  8. City of Philadelphia Code §10-2102 (civil-citation ordinance, Bill 140377, 2014)accessed May 17, 2026
  9. City of Pittsburgh Code of Ordinances (Municode) — civil-citation ordinance 2015-1739accessed May 17, 2026
  10. City of Harrisburg Codified Ordinances (Municode) — Chapter 3-509, Ordinance 4-2014accessed May 17, 2026
  11. NIH National Institute of Neurological Disorders and Stroke: Muscular Dystrophyaccessed May 18, 2026
  12. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026

    “Substantial evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy-induced nausea.”

  13. Muscular Dystrophy Association: About Neuromuscular Diseasesaccessed May 18, 2026
  14. MedlinePlus: Muscular dystrophyaccessed May 18, 2026
  15. FDA: Epidiolex (cannabidiol) prescribing informationaccessed May 18, 2026